公开(公告)号：US09309274B2

公开(公告)日：2016-04-12

申请号：US14488742

申请日：2014-09-17

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Milko E. Van Der Boom ,  Atindra D. Shukla ,  David Rosenblatt ,  Tarkeshwar Gupta

IPC: C07F15/00 ,  G02F1/15 ,  H01G9/22 ,  H01G9/20 ,  H01L51/00 ,  G01N27/30 ,  G01Q80/00 ,  G01N27/327 ,  C07F7/18

CPC classification number: C07F15/0026 ,  C07F7/1804 ,  C07F15/0053 ,  G01N27/30 ,  G01N27/305 ,  G01N27/3275 ,  G01Q80/00 ,  G02F1/15 ,  H01G9/2018 ,  H01G9/2059 ,  H01L51/0002 ,  H01L51/0086 ,  H01L51/0088 ,  Y02E10/542 ,  Y02E10/549 ,  Y10T29/49002

Abstract: A device is presented having reversibly changeable and optically readable optical properties. The device comprises a substrate having an electrically conductive surface and carrying a redox-active layer structure. The redox-active layer structure may be a monolayer or a multi-layer structure and is configured to have at least one predetermined electronic property including at least one of electrodensity and oxidation state. The electronic property of the layer structure defines an optical property of the structure thereby determining an optical response of the structure to certain incident light. This at least one electronic property is changeable by subjecting the redox-active layer structure to an electric field or to a redox-active material. The device thus enables effecting a change in said electronic property that results in a detectable change in the optical response of the layer structure.

Abstract translation: 呈现具有可逆变化和光学可读光学性质的装置。 该器件包括具有导电表面并承载氧化还原活性层结构的衬底。 氧化还原活性层结构可以是单层或多层结构，并且被配置为具有包括电密度和氧化态中的至少一种的至少一种预定的电子性质。 层结构的电子特性限定了该结构的光学特性，从而确定该结构对某些入射光的光响应。 通过使氧化还原活性层结构经受电场或氧化还原活性物质，该至少一种电子性质是可变化的。 因此，该装置能够实现导致层结构的光学响应的​​可检测变化的所述电子特性的变化。

公开(公告)号：US09289433B2

公开(公告)日：2016-03-22

申请号：US13872247

申请日：2013-04-29

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irina Lavelin ,  Varda Rotter ,  Moshe Oren ,  Ami Navon ,  Zvi Kam ,  Benjamin Geiger

IPC: A61K31/555 ,  A61K31/47 ,  A61K31/522 ,  A61K31/60 ,  A61K33/34 ,  C07K14/47 ,  C12N9/64 ,  G01N33/50 ,  A61K31/52

CPC classification number: A61K31/555 ,  A61K31/47 ,  A61K31/52 ,  A61K31/522 ,  A61K31/60 ,  A61K33/34 ,  C07K14/4746 ,  C07K2319/40 ,  C07K2319/60 ,  C12N9/6421 ,  C12Y304/25001 ,  G01N33/5035

Abstract: A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors.

Abstract translation: 提供了治疗其中抑制蛋白酶体的优点的疾病的方法。 该方法包括向受试者施用治疗有效量的结合细胞蛋白酶体的化合物，所述化合物包含与配体结合的铜，所述配体被配置为使得在结合蛋白酶体时，铜与半胱氨酸相互作用 31的蛋白酶体的β2亚基，并进一步与蛋白酶体的β3亚基的半胱氨酸118相互作用，从而治疗该疾病。 还提供了另外的新型蛋白酶体抑制剂以及鉴定蛋白酶体抑制剂的方法。

公开(公告)号：US20160051629A1

公开(公告)日：2016-02-25

申请号：US14781316

申请日：2014-04-09

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Anthony FUTERMAN ,  Einat VITNER ,  Ran SALOMON

IPC: A61K38/20

CPC classification number: A61K38/2006 ,  A61K45/06

Abstract: The present invention provides compositions and methods for treating lysosomal storage disease characterized by elevation of RIP kinase in a subject in need thereof using at least one RIP kinase inhibitor.

Abstract translation: 本发明提供用于治疗溶酶体贮积病的组合物和方法，其特征在于使用至少一种RIP激酶抑制剂在有需要的受试者中升高RIP激酶。

公开(公告)号：US09242231B2

公开(公告)日：2016-01-26

申请号：US13855258

申请日：2013-04-02

Applicant: Yeda Research and Development Co. Ltd. ,  NDSU Research Foundation

Inventor： Reshef Tenne ,  Yulia Tsverin ,  Uwe Burghaus ,  Mallikharjuna Rao Komarneni

IPC: B01J27/049 ,  B01J27/02 ,  B01J35/00 ,  B01J35/06 ,  C10G45/04 ,  B01D53/86 ,  B01J37/16 ,  B01J37/02

CPC classification number: B01J27/049 ,  B01D53/8687 ,  B01D2255/20776 ,  B01D2255/802 ,  B01D2257/70 ,  B01J27/02 ,  B01J35/0013 ,  B01J35/004 ,  B01J35/006 ,  B01J35/06 ,  B01J37/0217 ,  B01J37/16 ,  C02F2305/08 ,  C02F2305/10 ,  C10G45/04 ,  C10G2300/202 ,  C10G2300/70 ,  C10G2300/703 ,  Y02W10/37

Abstract: This invention relates to a hybrid component comprising at least one nanoparticle of inorganic layered compound (in the form of fullerene-like structure or nanotube), and at least one metal nanoparticle, uses thereof as a catalyst, (e.g. photocatalysis) and processes for its preparation.

Abstract translation: 本发明涉及包含至少一种无机层状化合物纳米颗粒（呈富勒烯结构或纳米管形式）的纳米颗粒和至少一种金属纳米颗粒，其用途作为催化剂（例如光催化剂）及其工艺 制备。

公开(公告)号：US20160008463A1

公开(公告)日：2016-01-14

申请号：US14850794

申请日：2015-09-10

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD

Inventor： Michal EISENBACH-SCHWARTZ ,  Kuti BARUCH ,  Neta ROSENZWEIG

IPC: A61K39/395 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

Abstract translation: 一种包含活性剂的药物组合物，其引起个体中用于治疗不包括自身免疫性神经炎症性疾病，复发性多发性硬化症（RRMS）的疾病，病症，病状或损伤的个体的全身免疫抑制水平的降低 ）。 药物组合物用于通过包含至少两个治疗疗程的剂量方案给药，每个治疗过程依次包括治疗会话，随后是间歇疗程的非治疗。

公开(公告)号：US09218365B2

公开(公告)日：2015-12-22

申请号：US13712982

申请日：2012-12-13

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Irani ,  Alon Faktor

IPC: G06K9/54 ,  G06K9/60 ,  G06F17/30 ,  G06K9/00 ,  G06K9/46 ,  G06K9/62

CPC classification number: G06F17/30244 ,  G06F17/30259 ,  G06K9/00677 ,  G06K9/4676 ,  G06K9/6215 ,  G06K9/6218

Abstract: Device, system, and method of visual inference by collaborative composition. A method of searching for similar target content-items for a plurality of source content-items, the method implementable on a computing device, comprises: for each of said plurality of source content-items, searching for similar target content-items in a dataset, while taking into account collaborative feedback exchanged among at least some of currently-searched said plurality of source content-items.

Abstract translation: 设备，系统和方法通过协同构成的视觉推理。 一种搜索用于多个源内容项目的类似目标内容项目的方法，所述方法可在计算设备上实现，包括：对于所述多个源内容项目中的每一个，在数据集中搜索类似的目标内容项目 同时考虑在至少一些当前搜索的所述多个源内容项之间交换的协作反馈。

公开(公告)号：US20150356704A1

公开(公告)日：2015-12-10

申请号：US14732843

申请日：2015-06-08

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Yaron LIPMAN ,  Roi PORANNE ,  Shahar Ziv KOVALSKY ,  Ronen Ezra BASRI ,  Noam AIGERMAN

IPC: G06T3/00 ,  G06T17/10 ,  G06T11/20 ,  G06F17/50

CPC classification number: G06T3/0093 ,  G06T13/20 ,  G06T19/20 ,  G06T2210/44 ,  G06T2219/2021

Abstract: A computer implemented method and system for simulating deformation of at least one physical object, the method using a processor to generate steps of: mapping the object using: a mesh of base-shapes, or, basis functions; controlling distortion of the deformation, by constraining or minimizing at least one of: isometric distortion, conformal distortion, and singular values of differentials of the mapping; and displaying the deformation via a display device.

Abstract translation: 一种用于模拟至少一个物理对象的变形的计算机实现的方法和系统，所述方法使用处理器来生成步骤：使用以下形式映射所述对象：基本网格，或基本函数; 通过约束或最小化映射差分的等距失真，保形失真和奇异值中的至少一个来控​​制变形的变形。 并通过显示装置显示变形。

公开(公告)号：US20150303524A1

公开(公告)日：2015-10-22

申请号：US14424039

申请日：2013-08-27

Applicant: Yeda Research and Development Co., Ltd.

Inventor： Michael EPSTEIN

IPC: H01M10/39

CPC classification number: H01M10/399 ,  H01M2/40 ,  H01M10/3909 ,  H01M10/4214 ,  H01M10/4242 ,  H01M10/46 ,  H01M10/615 ,  H01M10/66

Abstract: The invention relates to an energy conversion and storage system and a method wherein a battery catholyte composition (e.g., following or during a discharge process) is decomposed by heating to produce a decomposed catholyte and separate an anolyte component therefrom, thereby enabling use of the anolyte component and a remainder of the decomposed catholyte in anodic and cathodic half-cells of an electrochemical energy storage device.

Abstract translation: 本发明涉及一种能量转换和储存系统及其方法，其中电池阴极电解液组合物（例如，在放电过程之后或放电过程中）通过加热分解以产生分解的阴极电解液并从其中分离阳极电解质组分，由此使阳极电解液 在电化学储能装置的阳极和阴极半电池中分解的阴极电解液的其余部分和剩余部分。

公开(公告)号：US20150290233A1

公开(公告)日：2015-10-15

申请号：US14432520

申请日：2013-11-28

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef Yarden ,  Nir Ben-Chetrit

IPC: A61K31/7048 ,  A61K31/353 ,  A61K31/7034 ,  A61K31/704 ,  A61K31/12 ,  G01N33/574 ,  A61K31/155 ,  A61K31/4709 ,  A61K31/235 ,  A61K31/05 ,  A61K39/00 ,  A61K45/06 ,  A61K31/7032

CPC classification number: A61K31/7048 ,  A61K31/05 ,  A61K31/12 ,  A61K31/155 ,  A61K31/216 ,  A61K31/235 ,  A61K31/353 ,  A61K31/366 ,  A61K31/4709 ,  A61K31/7032 ,  A61K31/7034 ,  A61K31/704 ,  A61K38/179 ,  A61K39/0011 ,  A61K45/06 ,  C07K16/30 ,  G01N33/57415 ,  A61K2300/00

Abstract: A method of preventing tumor metastasis with the proviso that the tumor is not glioma is provided. The method comprising administering to a subject in need thereof a therapeutically effective amount of an inhibitor of synaptojanin 2 (SYNJ2), thereby preventing tumor metastasis. Also, provided is a method of treating cancer. The method comprising, administering to a subject in need thereof a therapeutically effective amount of an inhibitor of synaptojanin 2 (SYNJ2) and an inhibitor of a cell surface receptor associated with an onset or progression of cancer, thereby treating cancer.

Abstract translation: 提供了一种预防肿瘤转移的方法，条件是肿瘤不是神经胶质瘤。 所述方法包括向有需要的受试者施用治疗有效量的突触纲2（SYNJ2）抑制剂，从而防止肿瘤转移。 另外，提供了治疗癌症的方法。 该方法包括向有需要的受试者施用治疗有效量的突触纲2（SYNJ2）抑制剂和与癌症发病或进展相关的细胞表面受体的抑制剂，从而治疗癌症。

公开(公告)号：US20150284417A1

公开(公告)日：2015-10-08

申请号：US14702641

申请日：2015-05-01

Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

Inventor： David MILSTEIN ,  Ekambaram BALARAMAN ,  Chidambaram GUNANATHAN ,  Boopathy GNANAPRAKASAM ,  Jing ZHANG

IPC: C07F15/00 ,  C07D305/06 ,  C07D307/44 ,  C07D295/023 ,  C07K5/12 ,  C07C29/149 ,  C07C213/02 ,  C07C67/00 ,  C07C231/10 ,  C07D307/52 ,  C07D295/185 ,  C07C51/00 ,  C07D309/30 ,  C07D307/33 ,  C07D307/83 ,  C07D241/12 ,  C07K1/00 ,  C07B41/08 ,  C07B41/02 ,  C07B41/12 ,  C07B43/06 ,  C07B43/04 ,  B01J31/24 ,  C07C209/62

CPC classification number: C07K5/12 ,  B01J31/18 ,  B01J31/189 ,  B01J31/2404 ,  B01J31/2409 ,  B01J31/248 ,  B01J31/2485 ,  B01J2231/40 ,  B01J2231/49 ,  B01J2231/643 ,  B01J2231/763 ,  B01J2531/0244 ,  B01J2531/821 ,  C07B41/02 ,  C07B41/08 ,  C07B41/12 ,  C07B43/04 ,  C07B43/06 ,  C07C29/136 ,  C07C29/149 ,  C07C29/177 ,  C07C41/16 ,  C07C41/26 ,  C07C45/002 ,  C07C45/006 ,  C07C51/00 ,  C07C51/02 ,  C07C51/23 ,  C07C51/295 ,  C07C67/00 ,  C07C67/03 ,  C07C67/297 ,  C07C209/00 ,  C07C209/62 ,  C07C213/00 ,  C07C213/02 ,  C07C231/02 ,  C07C231/10 ,  C07C2601/08 ,  C07C2601/10 ,  C07C2601/14 ,  C07D207/06 ,  C07D207/08 ,  C07D211/12 ,  C07D213/38 ,  C07D241/08 ,  C07D241/12 ,  C07D295/023 ,  C07D295/027 ,  C07D295/185 ,  C07D305/06 ,  C07D307/14 ,  C07D307/33 ,  C07D307/44 ,  C07D307/52 ,  C07D307/83 ,  C07D309/30 ,  C07D487/14 ,  C07F9/58 ,  C07F9/65583 ,  C07F15/0046 ,  C07F15/0053 ,  C07K1/00 ,  C08G69/00 ,  Y02P20/52 ,  C07C233/05 ,  C07C235/06 ,  C07C233/07 ,  C07C235/16 ,  C07C235/14 ,  C07C235/10 ,  C07C211/27 ,  C07C211/07 ,  C07C211/35 ,  C07C211/46 ,  C07C211/10 ,  C07C215/28 ,  C07C217/58 ,  C07C69/14 ,  C07C69/24 ,  C07C31/125 ,  C07C31/12 ,  C07C49/78 ,  C07C49/04 ,  C07C49/10 ,  C07C49/08 ,  C07C49/403 ,  C07C31/205 ,  C07C31/202 ,  C07C31/04 ,  C07C31/08 ,  C07C33/20 ,  C07C33/22 ,  C07C31/1355 ,  C07C31/10 ,  C07C43/13 ,  C07C69/78 ,  C07C69/75 ,  C07C53/124 ,  C07C53/126 ,  C07C59/125 ,  C07C57/32 ,  C07C61/08 ,  C07C57/30 ,  C07C65/21 ,  C07C63/08 ,  C07C63/06

Abstract: The present invention relates to novel Ruthenium complexes and related borohydride complexes, and their use for (1) hydrogenation of amides (including polyamides) to alcohols and amines; (2) preparing amides from alcohols with amines (including preparing polyamides (e.g., polypeptides) by reacting dialcohols and diamines or by polymerization of amino alcohols); (3) hydrogenation of esters to alcohols (including hydrogenation of cyclic esters (lactones), cyclic di-esters (di-lactones) or polyesters); (4) hydrogenation of organic carbonates (including polycarbonates) to alcohols and of carbamates (including polycarbamates) or urea derivatives to alcohols and amines; (5) dehydrogenative coupling of alcohols to esters; (6) hydrogenation of secondary alcohols to ketones; (7) amidation of esters (synthesis of amides from esters and amines); (8) acylation of alcohols using esters; (9) coupling of alcohols with water to form carboxylic acids; and (10) dehydrogenation of beta-amino alcohols to form pyrazines. The present invention further relates to novel uses of certain pyridine Ruthenium complexes.

Abstract translation: 本发明涉及新型钌络合物和相关硼氢化物配合物及其用于（1）将酰胺（包括聚酰胺）氢化成醇和胺的用途; （2）由醇与胺（包括通过使二元醇和二胺反应制备聚酰胺（如多肽）或通过氨基醇的聚合）制备酰胺; （3）将酯氢化成醇（包括环酯（内酯）的加氢，环状二酯（二内酯）或聚酯））; （4）有机碳酸酯（包括聚碳酸酯）对醇和氨基甲酸酯（包括聚氨基甲酸酯）或脲衍生物氢化成醇和胺; （5）醇与酯的脱氢偶联; （6）将仲醇醇化成酮类; （7）酯的酰胺化（由酯和胺合成酰胺）; （8）使用酯酰化醇; （9）将醇与水偶联以形成羧酸; 和（10）β-氨基醇脱氢形成吡嗪。 本发明还涉及某些吡啶钌络合物的新用途。